极低危前列腺癌中雄激素剥夺治疗利用率的全国趋势
基于美国国家癌症数据库(NCDB)2010至2015年52,797例极低危前列腺癌患者,分析雄激素剥夺治疗(ADT)的使用趋势。结果显示,极低危患者中 primary ADT 使用率维持在0.7%,低容量机构治疗者(HR 1.29,P<.001)和黑人患者(HR 1.47,P<.001)更可能接受 primary ADT。作者认为 primary ADT 可能被过度使用,尤其在黑人和低容量机构治疗的患者中。
要点
- 2010至2015年极低危前列腺癌患者中 primary ADT 使用率维持在0.7%。
- 低容量机构治疗者接受 primary ADT 的可能性更高(HR 1.29,P<.001)。
- 黑人患者接受 primary ADT 的可能性更高(HR 1.47,P<.001)。
核心结论
- 极低危前列腺癌男性中 primary ADT 的使用随时间未变化,可能被过度使用,尤其在黑人和低容量机构治疗的患者中。
研究设计与样本
- 利用美国国家癌症数据库(NCDB)分析2010至2015年52,797例极低危前列腺癌患者(cT1cM0,PSA<10,Gleason≤6,活检阳性针数<3)的 primary ADT 使用趋势。
主要发现
- 2010至2015年,极低危前列腺癌患者中 primary ADT 使用率维持在0.7%。
- 低容量机构治疗的患者更可能接受 primary ADT(HR 1.29,P<.001)。
- 黑人患者更可能接受 primary ADT(HR 1.47,P<.001)。
- 随时间推移,接受 primary ADT 的白人男性比例下降,而黑人男性比例上升。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To analyze national trends using the National Cancer Database (NCDB) in use of androgen deprivation therapy (ADT), outside of standard of care, in patients with very low risk prostate cancer. METHODS: We identified 52,797 men in the NCDB from 2010 to 2015 diagnosed with very low risk prostate cancer as defined (cT1cM0, PSA <10, Gleason ≤6, <3 biopsy cores positive). We evaluated the treatment trends and the proportion of men treated with ADT based on race, income, insurance status, treatment facility volume, and Charlson comorbidity. RESULTS: From 2010 to 2015, prevalence of primary ADT use in patients with very low risk prostate cancer remained 0.7%. Patients treated at low-volume facilities were more likely to receive primary ADT (hazard ratio [HR] 1.29, P <.001) as were black patients (HR 1.47, P <.001). When evaluated over time, the proportion of men treated with primary ADT who were white decreased while the proportion of men who were black increased. CONCLUSION: The use of primary ADT in men with very low risk prostate cancer has not changed over time, and may be over utilized, particularly among black men and those treated at low-volume facilities.
引用
- May A, Henke J, Au D, et al. National Trends in the Utilization of Androgen Deprivation Therapy for Very Low Risk Prostate Cancer. Urology. 2019. PMID: 31047912. doi:10.1016/j.urology.2019.02.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。